Tocilizumab in Graves’ orbitopathy
2 February 2024
| Hetvi Bhatt
|
Oculoplastics, Orbit
|
Graves’ orbitopathy, Tocilizumab, corticosteroid
This prospective European study looks at the response to tocilizumab in corticosteroid-resistant disease. Tocilizumab (TCZ) is a monoclonal antibody that competitively inhibits IL-6 binding to its receptor. Unlike teprotumumab, the advantage of TCZ is that it is already used within...
A survey of neuro-ophthalmologists on use of corticosteroids in giant cell arteritis
1 December 2021
| Claire Howard
|
Neuro-Ophthalmology
|
Giant Cell Arteritis, corticosteroid, dosage, vasculitis, vision Loss
While corticosteroids are the mainstay of treatment in giant cell arteritis (GCA), the type, dose, route and duration of treatment remains controversial. The authors surveyed 180 neuro-ophthalmologists on their use of this treatment via email in a two-month period. Results...
Cystoid macular oedema following cataract surgery
1 October 2019
| Ivan Yip
|
EYE - Cataract, EYE - Refractive
|
NSAIDs, cataract, cataract surgery, corticosteroids, cystoid macular oedema
This review covers the history, incidence, diagnosis, risk factors, pathophysiology and medical management of postoperative macular oedema (PCMO), with a particular emphasis on key contemporary studies and novel observations. The authors revisit the incidence of well-established risk factors including intraoperative...
VKH outcomes with pulse IV steroids
1 April 2019
| Jonathan Chan
|
Retina / Uvea / Vitreous
|
Vogt-Koyanagi-Harada disease, corticosteroids, cyclosporine, treatment, visual outcome
This is a retrospective review of clinical case notes records of 111 Vogt-Koyanagi-Harada (VKH) patients between 1999 and 2015 from a single centre in Tokyo, Japan. The mean age at presentation was 41 years and the median follow-up period was...
